Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Petros Pharmaceuticals (NASDAQ:PTPI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Valuation & Earnings

This table compares MoonLake Immunotherapeutics and Petros Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$36.01 million	($1.29)	-33.96
Petros Pharmaceuticals	$5.82 million	0.52	-$8.16 million	($4.76)	-0.06

Petros Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares MoonLake Immunotherapeutics and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-15.54%	-15.09%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Analyst Recommendations

This is a summary of recent ratings and target prices for MoonLake Immunotherapeutics and Petros Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	0	1	6	1	3.00
Petros Pharmaceuticals	0	0	0	0	0.00

MoonLake Immunotherapeutics presently has a consensus price target of $84.29, suggesting a potential upside of 92.39%. Given MoonLake Immunotherapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe MoonLake Immunotherapeutics is more favorable than Petros Pharmaceuticals.

Risk and Volatility

MoonLake Immunotherapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.

Summary

MoonLake Immunotherapeutics beats Petros Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.